Topotecan: Designing Mechanism-First Cancer Assays
2026-09-04
Topotecan and SKF104864 are best understood through the relationship between Topo I trapping, lactone stability, and exposure timing. This mechanism-first guide translates pharmacology into better cancer research assays, with focused applications in glioma and pediatric tumor models.
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-04
CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor for investigating CDK9-dependent transcription elongation and HIV-1 propagation in defined biochemical and MT4 cell workflows. It should not be used as a pan-CDK reagent, a general cytotoxicity probe, or a long-term working-solution reagent.
Functional Metagenomics Reveals Potent Cas9 Inhibitors
2026-09-03
Forsberg et al. developed a functional metagenomic selection that identified anti-CRISPR proteins directly from human oral and fecal microbiomes. The study uncovered AcrIIA11, a potent inhibitor active against SpyCas9 in bacterial and human-cell contexts, and showed that functional screening can reveal Cas9 antagonists missed by sequence-based discovery.
IAM-LC vs LEKC for Pulmonary Drug Permeability
2026-09-03
This Journal of Chromatography A study directly compares immobilised artificial membrane liquid chromatography (IAM LC) with liposome electrokinetic capillary chromatography (LEKC) as biomimetic tools for drug–membrane partitioning and pulmonary permeability assessment. LEKC more closely reflected apparent lung permeability by incorporating hydrophobic and electrostatic interactions, whereas IAM LC provided broader analyte coverage and a simpler route to high-throughput screening.
Tetrazolium (chloride) for Ischemic Tissue Assays
2026-09-02
Tetrazolium (chloride), also called Tetrazolium Red or TTC, converts mitochondrial dehydrogenase activity into a measurable red formazan signal. This article shows how to apply it in oxidative-stress cell models and ex vivo ischemic brain tissue, with practical controls, optimization parameters, and troubleshooting guidance.
EZ Cap™ Cy5 EGFP mRNA (5-moUTP)
2026-09-02
Learn how EZ Cap™ Cy5 EGFP mRNA (5-moUTP), SKU R1011, separates cellular uptake from functional translation in viability, proliferation, cytotoxicity, and gene-delivery workflows. This scenario-driven guide covers assay design, handling, interpretation, and practical product-selection criteria.
RIPA Lysis Buffer (Strong) for Glioma Studies
2026-09-01
RIPA Lysis Buffer (Strong) enables high-stringency recovery of signaling proteins from glioma cells and brain tissue for Western blotting, ELISA, and selected immunoprecipitation workflows. This guide translates a recent CSRP2–PDGFRA study into practical sample-preparation choices while clarifying when strong detergent lysis should be replaced by a milder native-complex protocol.
Cucurbitacin I (JSI-124): STAT3 Research Guide
2026-09-01
Cucurbitacin I, also called JSI-124, is a context-dependent JAK2/STAT3 pathway probe for cancer research. Reported activity includes STAT3 phosphorylation and DNA-binding suppression, apoptosis, invasion control, chemosensitization, and tumor growth inhibition in vivo, but responses depend on model, endpoint, and exposure conditions.
tRF16–ALKBH5–NFKBIA Axis in Osteoarthritis
2026-08-31
This study identifies tRF16 as an overexpressed regulatory RNA that accelerates osteoarthritis through an ALKBH5-dependent m6A mechanism. Its data connect tRF16 binding to ALKBH5 with reduced NFKBIA mRNA stability, NF-κB activation, inflammatory signaling, and cartilage deterioration, suggesting a mechanistic biomarker and possible intervention point.
Gramine and the CUL3–MTDH Ferroptosis Opportunity
2026-08-30
Gramine is emerging as a mechanistically defined chemical probe for triple-negative breast cancer research. By connecting CUL3 activity, MTDH ubiquitination, redox control, and ferroptosis, it offers translational researchers a framework that extends beyond simple cytotoxicity screening.
AICAR Workflows for AMPK Metabolism Research
2026-08-29
AICAR provides a controllable AMPK perturbation for connecting energy metabolism regulation with mitochondrial quality control, glucose handling, and inflammatory signaling. This workflow translates findings from skeletal-muscle mitophagy research into practical assay design, dose selection, and troubleshooting decisions.
Viperin Blocks Coronavirus RTC Assembly via nsp8
2026-08-29
The 2026 reference study identifies a previously unrecognized antiviral mechanism in which viperin binds coronavirus nsp8 and disrupts replication-transcription complex assembly, reducing RNA-dependent RNA polymerase activity. Using porcine deltacoronavirus as a model, the work separates this protein-targeting mechanism from viperin-mediated ddhCTP production and highlights nsp8 as a potentially conserved target for antiviral drug development.
Pepstatin A in Reliable Cell Assays
2026-08-28
Learn how Pepstatin A (SKU A2571) can improve mechanistic interpretation of cell viability, proliferation, cytotoxicity, viral protein processing, and osteoclastogenesis experiments. This scenario-driven guide covers target selection, DMSO compatibility, dosing, controls, data interpretation, and practical product-selection criteria.
Masitinib (AB1010): KIT/PDGFR Workflow Guide
2026-08-28
Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for research involving KIT, PDGFRα, PDGFRβ, mast cells, and selected KIT-mutant cell models. It is useful for cancer biology, mastocytosis research, and inflammatory assays, but is unsuitable for protocols requiring aqueous or ethanol solubility, broad-spectrum kinase inhibition, or clinical treatment conclusions.
CLK2 and Platinum Resistance in Ovarian Cancer
2026-08-27
The reference study identifies Cdc2-like kinase 2 (CLK2) as a determinant of platinum resistance in ovarian cancer and links its activity to BRCA1 Ser1423 phosphorylation and DNA damage repair. Its combination of patient-tissue analysis, cellular assays, mechanistic studies, and xenograft validation provides a framework for evaluating CLK2 as a resistance-associated therapeutic target.
457 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page